JS Link, Inc.
Research JS Link, Inc. (127120.KQ) on Bullrun: market cap KRW 726.09B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker127120.KQ
- ExchangeKQ
- CountrySouth Korea
- SectorHealthcare
- IndustryBiotechnology
- CurrencyKRW
- Market capKRW 726.09B
- Financial periodQ2 2026
- RevenueKRW 6.31B
- Net incomeKRW 8.01B
- Free cash flow-KRW 13.44B
- Gross margin43.0%
Valuation Snapshot
latest market cap is KRW 726.09B.
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | KRW 726.09B | n/a | n/a | n/a |
Dividend history
About JS Link, Inc.
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is JS Link, Inc.'s market cap?
JS Link, Inc.'s market capitalization is KRW 726.09B.
What does JS Link, Inc. do?
JS Link, Inc., a genome-based biotechnology company, focuses on the research and development of genome analysis services in South Korea and internationally. Its next generation sequencing services include whole genome sequencing, De Novo sequencing, whole exome/targeted sequencing, transcriptome sequencing, epigenome sequencing, and single-cell RNA sequencing. The company also provides microarray services, such as DNA and microarray RNA analysis; Fluidigm BioMark System, an automated PCR/qPCR system; TaqMan assay; and SNaPshot assay. In addition, it provides rare earth and permanent magnets.